MIRVASO

This brand name is authorized in United States. It is also authorized in Austria, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Lithuania, Netherlands, New Zealand, Poland, Singapore, Spain, UK.

Active ingredients

The drug MIRVASO contains one active pharmaceutical ingredient (API):

1	Brimonidine UNII 4S9CL2DY2H - BRIMONIDINE TARTRATE
	Brimonidine is an alpha2-adrenergic receptor agonist that is 1000-fold more selective for the alpha2-adrenoceptor than the alpha1-adrenoreceptor. This selectivity results in no mydriasis and the absence of vasoconstriction in microvessels associated with human retinal xenografts.
	Read more about Brimonidine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MIRVASO Gel	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D11AX21		D Dermatologicals → D11 Other dermatological preparations → D11A Other dermatological preparations → D11AX Other dermatologicals
Discover more medicines within D11AX21

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1642463, 1642474, 1642485, 1816130, 1849653, 1849664
ES	Centro de información online de medicamentos de la AEMPS	113904006
FI	Lääkealan turvallisuus- ja kehittämiskeskus	524981
FR	Base de données publique des médicaments	68293613
GB	Medicines & Healthcare Products Regulatory Agency	241118
HK	Department of Health Drug Office	63413
IE	Health Products Regulatory Authority	13127
LT	Valstybinė vaistų kontrolės tarnyba	1075473, 1075474, 1075475, 1082360
NL	Z-Index G-Standaard, PRK	114375
NZ	Medicines and Medical Devices Safety Authority	17396
PL	Rejestru Produktów Leczniczych	100322657
SG	Health Sciences Authority	14828P
US	FDA, National Drug Code	0299-5980